Compare · NMRD vs SYK
NMRD vs SYK
Side-by-side comparison of Nemaura Medical Inc. (NMRD) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NMRD and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $115.59B, about 1268.6x NMRD ($91.1M).
- SYK has hit the wire 8 times in the past 4 weeks while NMRD has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 2 for NMRD).
- Company
- Nemaura Medical Inc.
- Stryker Corporation
- Price
- $0.12-5.38%
- $310.36+2.90%
- Market cap
- $91.1M
- $115.59B
- 1M return
- -
- +8.68%
- 1Y return
- -
- -18.80%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 2
- 25
Nemaura Medical Inc.
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company was founded in 2009 and is based in New York, New York.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest NMRD
- Nemaura Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form DEF 14C filed by Nemaura Medical Inc.
- SEC Form NT 10-K filed by Nemaura Medical Inc.
- Nemaura Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Nemaura Medical Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form PRE 14C filed by Nemaura Medical Inc.
- CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICA
- Nemaura Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Nemaura Medical Inc.
- Nemaura Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation